Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.65 |
| ▸ | BTK | Q06187 | 4/20 | 0.61 |
| ▸ | ITK | Q08881 | 4/20 | 0.61 |
| ▸ | JAK3 | P52333 | 6/20 | 0.59 |
| ▸ | BMX | P51813 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | JAK1 | P23458 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17797488 | 1.00 | EGFR (0.65) | EGFRBTKITKJAK3BMX | |
| SCHEMBL17813222 | 0.89 | KMT2A (0.57) | EGFRBTKITKJAK3BMX | |
| SCHEMBL3433250 | 0.88 | KMT2A (0.61) | EGFRBTKITKJAK3BMX | |
| SCHEMBL20774201 | 0.88 | KMT2A (0.61) | EGFRBTKITKJAK3BMX | |
| SCHEMBL14675141 | 0.88 | KMT2A (0.61) | EGFRBTKITKJAK3BMX | |
| SCHEMBL17813212 | 0.87 | EGFR (0.65) | EGFRBTKITKJAK3BMX | |
| SCHEMBL30366577 | 0.86 | EGFR (0.67) | EGFRBTKITKJAK3BMX | |
| SCHEMBL17797645 | 0.86 | BTK (0.58) | EGFRBTKITKJAK3JAK1 | |
| SCHEMBL17797646 | 0.86 | BTK (0.58) | EGFRBTKITKJAK3JAK1 | |
| SCHEMBL17813360 | 0.85 | EGFR (0.62) | EGFRBTKITKJAK3BMX |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190068-A1 | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | CHEN ZHIHONG (US) | 2020-06-18 | — | — | US | disclosed |
| WO-2019046163-A1 | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | ZHIHONG CHEN (US) | 2019-03-07 | — | — | WO | disclosed |
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE CAR LLC (BM) | 2016-06-09 | — | — | US | disclosed |
| WO-2016090079-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
| WO-2016090079-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | CELGENE AVILOMICS RESEARCH, INC. (US) | 2016-06-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190068-A1 | SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND THERAPEUTIC METHODS THEREOF | BTK, PTK2, LCK | EGFR 394/4885BTK 1/4885ITK 176/4885 |
| US-20160159774-A1 | HETEROARYL COMPOUNDS AND USES THEREOF | ABCG2, CYP3A43, CYP3A5 | EGFR 1981/4885BTK 594/4885ITK 2697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.